We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05170009
Recruitment Status : Recruiting
First Posted : December 27, 2021
Last Update Posted : June 28, 2022
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
This is a randomized, double-blind, placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with oseltamivir (standard of care) for the treatment of influenza in allogeneic stem cell transplant patients. Although there are no data about this treatment option currently available, the investigator hypothesizes that combination therapy may be more effective in clearing influenza virus infection and decreasing the rate of emergence of resistant influenza in immunocompromised human hosts.

Condition or disease Intervention/treatment Phase
Influenza Drug: Baloxavir Marboxil Drug: Placebo Drug: Oseltamivir Phase 2 Phase 3

Detailed Description:

This is a randomized double-blind placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with oseltamivir (standard of care) for the treatment of influenza in allogeneic stem cell transplant patients. 30 SCT recipients will take part in the study. Participants with be randomly assigned (1:1) to either baloxavir + oseltamivir or baloxavir-matched placebo +oseltamivir. Before randomization, patients will be stratified by hospitalization status and influenza type A (yes/no).

Patients in the baloxavir combination arm will receive weight-adjusted baloxavir (40 mg for patients weighing <80 kg and 80 mg for those weighing ≥80 kg) at baseline and at day 4 and day 7. They will also receive oseltamivir 75 mg twice daily for 10 days. Patients in the baloxavir-matched placebo + oseltamivir arm will receive baloxavir-matched placebo at baseline and at day 3 and day 7and oseltamivir 75 mg twice daily for 10 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Double-blind, Placebo-controlled Single Center Pilot Study to Evaluate the Efficacy and Safety of Baloxavir in Combination With Oseltamivir in Adult Allogeneic Bone Marrow Transplant Recipients With Influenza
Actual Study Start Date : April 22, 2022
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : October 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Active and standard of care
Active Baloxavir Marboxil and standard of care Oseltamivir
Drug: Baloxavir Marboxil
Weight-adjusted Baloxavir Marboxil (40 mg for patients weighing <80 kg and 80 mg for those weighing ≥80 kg) at baseline, day 4, and day 7.
Other Name: Xofluza

Drug: Oseltamivir
Oseltamivir 75 mg twice daily for 10 days.
Other Name: Tamiflu

Placebo Comparator: Placebo and standard of care
Placebo-matched Baloxavir Marboxil and standard of care Oseltamivir
Drug: Placebo
Placebo at baseline, day 4, and day 7.

Drug: Oseltamivir
Oseltamivir 75 mg twice daily for 10 days.
Other Name: Tamiflu




Primary Outcome Measures :
  1. Change of influenza viral RNA loads from baseline at the end of treatment as measured by quantitative real time polymerase chain reaction. [ Time Frame: Baseline; Day 10 ]
    Influenza viral RNA loads will be measured by quantitative real time polymerase chain reaction.

  2. Between-treatment-arm difference in the change of influenza viral RNA loads from baseline at the end of treatment as measured by quantitative real time polymerase chain reaction. [ Time Frame: Baseline; Day 10 ]
    Influenza viral load will be measured by the quantitative real time polymerase chain reaction.

  3. Between-treatment-arm difference in the change of influenza viral RNA loads from baseline at the end of treatment as measured by influenza plaque assay (replicating virus). [ Time Frame: Baseline; Day 10 ]
    Influenza viral load will be measured by the influenza plaque assay.


Secondary Outcome Measures :
  1. Change of influenza viral RNA load from baseline at day 4 and day 7 and 10 in each treatment arm [ Time Frame: Baseline; Day 4; Day 7; Day 10 ]
    Influenza viral RNA load will be measured by quantitative real time polymerase chain reaction.

  2. Difference in change of influenza viral loads from baseline at day 4, 7 and 10 between the two treatment arms as measured by quantitative real time polymerase chain reaction [ Time Frame: Baseline; Day 4; Day 7; Day 10 ]
    Influenza viral RNA load will be measured by quantitative real time polymerase chain reaction.

  3. Change of influenza viral loads from baseline at day 4, 7 and 10 as measured by influenza plaque assay (replicating virus) in each treatment arm [ Time Frame: Baseline; Day 4; Day 7; Day 10 ]
    Influenza viral load will be measured by the influenza plaque assay (replicating virus).

  4. Difference in change of influenza viral loads from baseline at day 4, 7 and 10 between the two treatment arms as measured by influenza plaque assay (replicating virus) [ Time Frame: Baseline; Day 4; Day 7; Day 10 ]
    Influenza viral load will be measured by the influenza plaque assay (replicating virus).

  5. Time to improvement of individual influenza symptoms as assessed by patient-reported outcome measures on a single scale [ Time Frame: Baseline to Day 30 ]
    Patients will self-assess the severity of 7 influenza-associated symptoms on a 4-point single scale with 0 indicating no symptoms and higher scores indicating mild, moderate, and severe symptoms. Time to improvement of individual influenza symptoms are defined as the time from the start of treatment to the time when each of the influenza symptoms are alleviated, maintained, or improved for a duration of at least 21.5 hours. These are defined as: pre-existing symptoms (cough, fatigue, or muscle/join pain that existed prior to influenza) that were worse at baseline and had improved at least 1 point from baseline; pre-existing symptoms not worse at baseline that maintained baseline severity; and new symptoms that were alleviated, defined as a symptom score of non (0) or mild (1).

  6. Percentage of patients who experience each influenza-related complications: hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia as an adverse event after the initiation of study treatment [ Time Frame: Day 1 to Day 30 ]
    A composite score of multiple measures will be used and calculated by count of patients who experience each influenza-related complications. Adverse events will only include those that are determined to be related to the study drug.

  7. Time to return to preinfluenza health status [ Time Frame: Day 1 to Day 30 ]
    Preinfluenza health status will be measured on a score from 0 (worst possible health) to 10 (normal health [for someone your age and condition]).

  8. Time to viral clearance, as assessed by difference in Percentage of Participants Positive by influenza plaque assay at each time-point (in each treatment group) [ Time Frame: Baseline to Day 30 ]
    Time to viral clearance will be assessed by percentage of participants positive by influenza plaque assay at each time-point.

  9. Time to viral clearance, as assessed by difference in Percentage of Participants Positive by quantitative real time polymerase chain reaction [ Time Frame: Baseline to Day 30 ]
    Time to viral clearance will be assessed by percentage of participants positive by qPCR at each time-point.

  10. Change of treatment-emergent variants of neuraminidase and polymerase known to confer antiviral resistance to oseltamivir in each arm by direct next-generation sequencing symptoms [ Time Frame: Baseline to Day 30 ]
    Treatment-emergent variants will be identified using direct next-generation sequencing of a comprehensive panel of genes.

  11. Percentage of participants with adverse events (AEs) [ Time Frame: Day 1 to Day 15 ]
    Adverse events will only include those that are determined to be related to the study drug and will assess the safety and tolerability of Baloxavir in Combination with SOC treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients: Signed informed consent by any patient capable of giving consent, or, where the patient is not capable of giving consent, by his or her legal/authorized representative
  • Age greater than or equal to 18 years at the time of signing the Informed Consent Form/Assent Form
  • Ability to comply with the study protocol, in the investigator's judgment
  • Have received allogeneic bone marrow transplant
  • Tested positive for influenza infection after the onset of symptoms using a polymerase chain reaction (PCR)-based diagnostic assay.
  • Presence of (a) fever (≥38.0 °C per tympanic or rectal thermometer; ≥ 37.5 °C per axillary, oral or forehead/temporal thermometer) or (b) any influenza symptoms (cough, sore throat, nasal congestion, headache, feverishness or chills, muscle or joint pain, fatigue).
  • The time interval between the diagnosis of influenza and the pre-dose examinations is 48 hours or less.
  • For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse):
  • Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 28 days after the last dose of study treatment. Hormonal contraceptive methods must be supplemented by a barrier method. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state greater than or equal to 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Exclusion Criteria:

  • Patients who have received more than 48 hours of antiviral treatment for the current influenza infection prior to screening
  • Patients who have received Baloxavir for the current influenza infection
  • Known contraindication to neuraminidase inhibitors
  • Patients weighing < 40 kg
  • Patients unable to swallow tablets
  • Patients with known severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis
  • Patients with any of the following laboratory abnormalities detected within 24 hours prior to or during screening (according to local laboratory reference ranges: ALT or AST level > 5 times the upper limit of normal (ULN) OR ALT or AST > 3 times the ULN and total bilirubin level > 2 times the ULN
  • Pregnant or breastfeeding, or positive pregnancy test in a predose examination, or intending to become pregnant during the study or within 28 days after the last dose of study treatment
  • Exposure to an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
  • Known hypersensitivity to baloxavir marboxil or the drug product excipients
  • Known COVID-19 coinfection
  • Unwilling to undergo nasopharyngeal (NP) swabs as per study schedule

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05170009


Contacts
Layout table for location contacts
Contact: Mirella Salvatore, MD 646-318-8506 mis2053@med.cornell.edu
Contact: Anna Gwak, BA 212-746-4089 ang4021@med.cornell.edu'

Locations
Layout table for location information
United States, New York
Weill Cornell Medicine Recruiting
New York, New York, United States, 10065
Contact: Anna Gwak, BA    202-746-4089    ang4021@med.cornell.edu   
Contact: Elizabeth L Salsgiver, MPH    212-746-4089    els7021@med.cornell.edu   
Principal Investigator: Mirella Salvatore, MD         
Sponsors and Collaborators
Weill Medical College of Cornell University
Genentech, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Mirella Salvatore, MD Weill Medical College of Cornell University
Additional Information:
Publications:
Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, Anovadiya AP, Azziz-Baumgartner E, Baez C, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarria M, Fanella S, Gao Z, Gerardin P, Giannella M, Gubbels S, Herberg J, Iglesias AL, Hoger PH, Hu X, Islam QT, Jimenez MF, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kusznierz G, Kuzman I, Kwan AM, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Mayo-Montero E, McGeer A, Memish Z, Metan G, Mickiene A, Mikic D, Mohn KG, Moradi A, Nymadawa P, Oliva ME, Ozkan M, Parekh D, Paul M, Polack FP, Rath BA, Rodriguez AH, Sarrouf EB, Seale AC, Sertogullarindan B, Siqueira MM, Skret-Magierlo J, Stephan F, Talarek E, Tang JW, To KK, Torres A, Torun SH, Tran D, Uyeki TM, Van Zwol A, Vaudry W, Vidmar T, Yokota RT, Zarogoulidis P; PRIDE Consortium Investigators; Nguyen-Van-Tam JS. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014 May;2(5):395-404. doi: 10.1016/S2213-2600(14)70041-4. Epub 2014 Mar 19.

Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT05170009    
Other Study ID Numbers: 20-12023076
First Posted: December 27, 2021    Key Record Dates
Last Update Posted: June 28, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Weill Medical College of Cornell University:
Influenza
Bone marrow transplant
Flu
Baloxavir Marboxil
Xofluza
Oseltamivir
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Respiratory Tract Infections
Infections
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases
Oseltamivir
Baloxavir
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action